Pharmafile Logo

Article: Market access in Brazil

All eyes on Spinraza

Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient’s health.

In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.

Read more on this article here: https://bit.ly/2qZ5HW1

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the...

Precision Medical Affairs in Action: Using AI and Analytics to Elevate Strategy, Engagement, and Impact

Discover how AI, analytics and real-world data are reshaping Medical Affairs.

How did multifaceted support from across Inizio help a biotech firm prepare for launch?

Discover how teams from across Inizio provided a range of integrated services to give a client's product the best chance of launch success.

Our key takeaways from ISMPP EU 2026 – Evolving with Purpose: Excellence in an Era of Efficiency

Explore Inizio Medical's key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.

Intelligent field team engagement: Turning shared knowledge into deeper insights and better decisions.

At Age of AI 2026, Inizio Medical’s Phil Wakefield and Inizio Ignite’s Tim Luxford will explore how cross-functional collaboration and AI can unlock faster, more actionable insights across medical and...

AI in practice: 4 real-world use cases in health and life sciences

Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it...

How will AI change field training?

Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force effectiveness by delivering scalable, always-on,...

Inizio Ignite Sparks a New Era of Connected Advisory Solutions

Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what...